ALK licenses rights to neffy, an adrenaline nasal spray for emergency treatment of anaphylaxis
ALK also gains rights to future indications, including acute urticaria flares (in development)
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
ARS Pharmaceuticals
ARS Pharmaceuticals’ Neffy poised to disrupt epinephrine market as first needle-free nasal spray:…
Neffy set to challenge injectable epinephrine devices with needle-free ease, but faces hurdles in proving real-world effectiveness…